Abstract: The present invention provides a radio-opaque composition comprising a cleavable, preferably enzymatically-cleavable, derivative of a physiologically tolerable organoiodine compound and a non-acrylic polymer wherein said derivative is incorporated in said non-acrylic polymer.

Abstract: The present invention provides a bone cement comprising in admixture a monomer-containing liquid portion and a particulate polymer portion, wherein at least one of the portions comprises a dissolved nonpolymerizable organoiodine compound.

Abstract: The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents of formula I wherein n is 0 or 1, and where n is 1 each C6R5 moiety may be the same or different; X denotes a bond or a group providing a 1 to 7 atom chain linking two C6R5 moieties or, where n is 0, X denotes a group R; each group R is a hydrogen atom, an iodine atom or a hydrophilic moiety M or M1, two or three non-adjacent R groups in each C6R5 moiety being iodine and at least one R group in each C6R5 moiety being an M or M1 moiety; each M which may be the same or different, is a non-ionic hydrophilic moiety; and each M1 independently represents a —CHOHCON(R1)2 group wherein each R1, which may be the same or different, is a hydrogen atom, an OH group or a C1-6 alkoxy or optionally hydroxylated C1-5 alkyl group; at least one R group in the molecule being an M1 moiety; and isomers thereof.

Abstract: The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents, of formula C6R6 wherein three non-adjacent R groups are iodine and the remaining R groups are non-ionic, hydrophilic moieties, said compound being water soluble at 20° C. to a concentration of at least 350 mgl/ml and which in aqueous solution at 20° C. at a concentration of 350 mgl/ml has a viscosity no greater than 13.8 mPas.

Abstract: The use in diagnostic imaging, in particular X-ray, MRI, ultrasound and scintigraphy, of contrast agents comprising bismuth clusters and/or organic bismuth compounds, and contrast media containing such bismuth compounds. The bismuth compounds are also useful in therapy, in particular as antimicrobial agents and antiulcer agents. Novel bismuth compounds are also disclosed.

Abstract: A method of generating an image of a human or non-human animal body which comprises administering to said body a physiologically tolerable contrast enhancing amount of a non-cluster type bismuth compound, and methods of treating gastrointestinal disorders using the same. Diagnostic imaging contrast media comprising non-cluster type bismuth compounds are also disclosed, together with novel covalent non-cluster type bismuth compounds.

Abstract: The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents, of formula I ##STR1## (wherein n is 0 or 1, and where n is 1 each C.sub.6 R.sub.5 moeity may be the same or different; each group R is a hydrogen atom, an iodine atom or a hydrophilic moiety M or M.sub.1, two or three non-adjacent R groups in each C.sub.6 R.sub.5 moiety being iodine and at least one, and preferably two or three, R groups in each C.sub.6 R.sub.5 moiety being M or M.sub.1 moieties; X denotes a bond or a group providing a 1 to 7 atom chain linking two C.sub.6 R.sub.5 moieties or, where n is 0, X denotes a group R; each M independently is a non-ionic hydrophilic moiety; and each M.sub.1 independently represents a C.sub.1-4 alkyl group substituted by at least one hydroxyl group and optionally linked to the phenyl ring via a carbonyl, sulphone or sulphoxide group, at least one R group being an M.sub.1 moiety; with the proviso that where n is zero either at least one M.sub.

Abstract: The invention provides iodinated bis phenyl compounds, useful as X-ray contrast agents, of formula (I) (wherein each C.sub.6 R.sub.5 moiety may be the same or different; each denotes a hydrogen or iodine atom or a group M, two or three non-adjacent R groups on each C.sub.6 R.sub.5 moiety denoting iodine atoms and one, two or three R groups on each C.sub.6 R.sub.5 moiety denoting M groups; X denotes a group providing a 1, 2 or 3 atom chain linking the two C.sub.6 R.sub.5 groups, preferably where X is or contains in the bridging chain a carbonyloxy group each C.sub.6 R.sub.5 group being a triodophenyl group or a group in which each R is other than hydrogen; and each M is independently a non-ionic hydrophilic moiety, M preferably being a non-ionic hydrophilic moiety comprising a monohydroxy- or polyhydroxy-alkyl group) and isomers, especially stereoisomers and rotamers, thereof.

Abstract: The invention provides iodinated bis phenyl compounds, useful as X-ray contrast agents, of formula I ##STR1## (wherein each C.sub.6 R.sub.5 moeity may be the same or different; each R denotes a hydrogen or iodine atom or a group M, two or three non-adjacent R groups on each C.sub.6 R.sub.5 moiety denoting iodine atoms and one, two or three R groups on each C.sub.6 R.sub.5 moiety denoting M groups;X denotes a group providing a 1, 2 or 3 atom chain linking the two C.sub.6 R.sub.5 groups, preferably where X is or contains in the bridging chain a carbonyloxy group each C.sub.6 R.sub.5 group being a triodophenyl group or a group in which each R is other than hydrogen; and each M is independently a non-ionic hydrophilic moiety, M preferably being a non-ionic hydrophilic moiety comprising a monohydroxy- or polyhydroxy-alkyl group) and isomers, especially stereoisomers and rotamers, thereof.

Abstract: An x-ray contrast medium containing a multinuclear complex of the formula (M.sub.6 (.mu..sub.3 B).sub.8 A.sub.v).sub.x L.sub.w, wherein M is Mo, W, Re Tc, V, Nb, Ta, Ru, or Fe; .mu..sub.3 B represent a tridentate bridging atom; A is a non-bridging atom; L is a ligand coordinately bonded to at least one M atom; x is a positive integer; and v and w are independently zero or positive integers.

Abstract: The invention provides low viscosity iodinated aryl compounds, useful as X-ray contrast agents, of formula I ##STR1## (wherein n is 0 or 1, and where n is 1 each C.sub.6 R.sub.5 moeity may be the same or different; each group R is a hydrogen atom, an iodine atom or a hydrophilic moiety M or M.sub.1, two or three non-adjacent R groups in each C.sub.6 R.sub.5 moiety being iodine and at least one, and preferably two or three, R groups in each C.sub.6 R.sub.5 moiety being M or M.sub.1 moieties; X denotes a bond or a group providing a 1 to 7 atom chain linking two C.sub.6 R.sub.5 moieties or, where n is 0, X denotes a group R; each M independently is a non-ionic hydrophilic moiety; and each M.sub.1 independently represents a C.sub.1-4 alkyl group substituted by at least one hydroxyl group and optionally linked to the phenyl ring via a carbonyl, sulphone or sulphoxide group, at least one R group being an M.sub.1 moiety; with the proviso that where n is zero either at least one M.sub.

Abstract: The present invention relates to a method of generating an electron spin resonance enhanced magnetic resonance image of a sample which comprises introducing into the sample a magnetic resonance signal enhancing amount of a free radical and generating an enhanced electron spin resonance image of the sample. The method comprises using as the free radical an inert triarylmethyl free radical, wherein each aryl moiety of said triarylmethyl radical, which may be identical or different, comprises an optionally substituted 6-membered carbocyclic or thienyl ring. The invention also relates to the use of trityls in ESR imaging.

Abstract: The use in diagnostic imaging, in particular X-ray, MRI, ultrasound and scintigraphy, of contrast agents comprising bismuth clusters and/or organic bismuth compounds, and contrast media containing such bismuth compounds. The bismuth compounds are also useful in therapy, in particular as antimicrobial agents and antiulcer agents. Novel bismuth compounds are also disclosed.

Abstract: A radical compound of formula Ia.C(Ar.sup.12).sub.3 (Ia)wherein:each Ar.sup.12, which may be the same or different, represents a 6-membered carbocyclic, at least one group Ar.sup.12 being a group Ar.sup.1 ;each group Ar.sup.1 represents a 6-membered ring optionally substituted at the or any ortho carbon by a group R.sup.1, R.sup.2, R.sup.3 or R.sup.4, at the or any meta carbon by a group R.sup.2 or R.sup.3, and at any para carbon by a group R.sup.1, R.sup.2, R.sup.3 or R.sup.4,with the proviso that no more than two ring carbons are unsubstituted;each of R.sup.1, R.sup.2, R.sup.3 or R.sup.4, which may be the same or different, independently represents a group of formula --M, --XM, --XAr.sup.2 or --Ar.sup.2 ;M represents a water solubilizing group, each group X, which may be the same or different, represents an oxygen or sulphur atom or a NH or CH.sub.2 group.

Abstract: There are provided chelating agents particularly useful for the preparation of diagnostic and therapeutic agents for magnetic resonance imaging, scintigraphy, ultrasound imaging, radiotherapy and heavy metal detoxification, said agents being compounds of formula IX--CHR.sub.1 --NZ--(CHR.sub.1).sub.n --A--(CHR.sub.1).sub.m --NZ--CHR.sub.1 --X (I)wherein n and m are 2, 3 or 4; and A, X, R.sub.1 and Z are as defined in the specification.

Abstract: An imaging contrast medium comprising a physiologically tolerable multinuclear complex (as defined in claim 1) is disclosed. The multinuclear complex contains at least two, but preferably three or more contrast enhancing atoms. For X-ray or ultrasound imaging techniques heavy metal atoms are used to enhance contrast, whereas in Magnetic Resonance Imaging paramagnetic metal atoms are contrast enhancing. Molybdenum and tungsten are preferred contrast enhancing atoms. The medium may also be used therapeutically.

Abstract: The invention relates to the use as contrast enhancing agents in medical imaging, especially X-ray imaging, of multinuclear complexes, i.e. complexes, such as those of W2O2 (u2O)2, in which the complexed entity comprises at least two contrast enhancing atoms.

Abstract: The decrease in cardiac contractile force which occurs in angiography using contrast media may be reduced without increasing the incidence of ventricular fibrillations by oxygenating the contrast media.

Abstract: Heterocyclic chelating agents and salts thereof of formula I: ##STR1## wherein X represents a bond, O or S, or a group CHR.sup.1 or NR.sup.3, each R.sup.1 represents H, a group OR.sup.3 or NR.sup.3 R.sup.3, or an alkyl or alkoxyalkyl group optionally substituted by a hydroxyl group or by a group NR.sup.3 R.sup.3 or CON.sup.3 R.sup.3 ;each R.sup.2 represents H, or an alkyl or alkoxy group optionally substituted by a hydroxyl or aloxy group;each R.sup.3 represents H, an optionally hydroxylated alkyl group or a group CH.sub.2 Y;Y represents a group COZ, CON(OH)R.sup.4, POZ.sub.2 or SO.sub.2 Z; Z represents a group OR.sup.4, NR.sup.4 R.sup.4 or ##STR2## where each R.sup.11 is H, a hydroxyl group or an optionally hydroxylated alkyl group, s is 0, 1 or 2, and W is CHR.sup.11, NR.sup.11 or an oxygen atom; andeach R.sup.4 represents H, or an optionally mono- or poly-hydroxylated alkyl, alkoxyalkyl or polyalkoxyalkyl group;with the provisos that where s is O then W is CHR.sup.

Abstract: The physiological acceptability of contrast media, especially media for use in angiography, may be enhanced by inclusion of sub-plasma levels of sodium and calcium and, optionally, potassium and/or magnesium, for example 30 mM Na, 0.15 mM Ca, 0.9 mM K and 0.1 mM Mg.